Jonathan Ostrem

Dr. Jonathan Ostrem is a thoracic medical oncologist who cares for patients with lung and other chest cancers, including non-small cell lung cancer, small cell lung cancer, thymoma and thymic carcinoma, and mesothelioma.

Ostrem is interested in cancer treatments that target tumors at the molecular level, and his research focuses on drug development. His work led to the development of sotorasib (Lumakras), the first targeted therapy to be approved by the Food and Drug Administration for patients with KRAS-mutant lung cancer. His lab works on designing new targeted therapies for lung cancer, with the goal of overcoming treatment resistance, as well as treatment approaches that can be used for a wide range of cancer types.

Ostrem earned his medical degree from UCSF. He completed a residency in internal medicine at Brigham and Women's Hospital, followed by a fellowship in hematology-oncology at the Dana-Farber Cancer Institute.